[go: up one dir, main page]

TR200402300T4 - İmidazopirimidin türevleri ve triazolopirimidin türevleri. - Google Patents

İmidazopirimidin türevleri ve triazolopirimidin türevleri.

Info

Publication number
TR200402300T4
TR200402300T4 TR2004/02300T TR200402300T TR200402300T4 TR 200402300 T4 TR200402300 T4 TR 200402300T4 TR 2004/02300 T TR2004/02300 T TR 2004/02300T TR 200402300 T TR200402300 T TR 200402300T TR 200402300 T4 TR200402300 T4 TR 200402300T4
Authority
TR
Turkey
Prior art keywords
optionally substituted
derivatives
imidazopyrimidine
triazolopyrimidine
alkyl
Prior art date
Application number
TR2004/02300T
Other languages
English (en)
Inventor
Yura Takeshi
B. Concepcion Arnel
Han Gyoonhee
Hiraoka Makiko
Katsumata Hiroko
Kawamura Norihiro
Kokubo Toshio
Komura Hiroshi
Li Yingfu
B. Lowinger Timothy
Mogi Muneto
Yamamoto Noriyuki
Yoshida Nagahiro
Wang Ming
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of TR200402300T4 publication Critical patent/TR200402300T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

R1'in-X-R4, istege bagli olarak ikameli bir heterosiklil kalinti, istege bagli olarak ikameli bir karbosiklik kalinti veya istege bagli olarak ikameli yogunlasmis halka yarisi; X'in CR5R6,O,S,SO,SO2 veya NR7; Y'nin CH veya N; R2'nin H, istege bagli olarak ikameli bir C1-C10 alkil vb.; R3'ün istege bagli olarak ikameli aril veya istege bagli olarak ikameli bir heteroaril vb.; R4'ün istege bagli olarak ikameli bir aril, istege bagli olarak ikameli bir heteroaril vb. oldugu; R5,R6 ve R7'nin ayni veya farkli oldugu ve H, istege bagli olarak ikameli bir C1-C10 alkili vb. temsil ettigi bir formül (I) bilesigi. Bilesik mükemmel antialerjik etkinlige ve benzerine sahiptir.
TR2004/02300T 2000-04-28 2001-04-17 İmidazopirimidin türevleri ve triazolopirimidin türevleri. TR200402300T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体

Publications (1)

Publication Number Publication Date
TR200402300T4 true TR200402300T4 (tr) 2004-12-21

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/02300T TR200402300T4 (tr) 2000-04-28 2001-04-17 İmidazopirimidin türevleri ve triazolopirimidin türevleri.

Country Status (38)

Country Link
US (1) US6911443B2 (tr)
EP (1) EP1278750B1 (tr)
JP (2) JP2001302667A (tr)
KR (1) KR20030009456A (tr)
CN (1) CN1263756C (tr)
AR (1) AR033367A1 (tr)
AT (1) ATE272639T1 (tr)
AU (1) AU783043B2 (tr)
BG (1) BG107166A (tr)
BR (1) BR0110404A (tr)
CA (1) CA2407531A1 (tr)
CZ (1) CZ20023551A3 (tr)
DE (1) DE60104671T2 (tr)
DK (1) DK1278750T3 (tr)
DO (1) DOP2001000151A (tr)
EE (1) EE200200606A (tr)
ES (1) ES2225546T3 (tr)
HK (1) HK1058362A1 (tr)
HR (1) HRP20020943A2 (tr)
HU (1) HUP0300846A2 (tr)
IL (1) IL151919A0 (tr)
MA (1) MA25746A1 (tr)
MX (1) MXPA02010579A (tr)
MY (1) MY141578A (tr)
NO (1) NO20025154D0 (tr)
NZ (2) NZ526221A (tr)
PE (1) PE20011287A1 (tr)
PL (1) PL358106A1 (tr)
PT (1) PT1278750E (tr)
RU (1) RU2306313C2 (tr)
SI (1) SI1278750T1 (tr)
SK (1) SK15332002A3 (tr)
SV (1) SV2001000416A (tr)
TR (1) TR200402300T4 (tr)
TW (1) TWI222974B (tr)
UA (1) UA72615C2 (tr)
WO (1) WO2001083485A1 (tr)
ZA (1) ZA200207676B (tr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60216747T2 (de) 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
JPWO2005037837A1 (ja) * 2003-10-17 2006-12-28 日本化薬株式会社 置換２−アミノ−［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体及びその用途
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
RU2373208C2 (ru) * 2004-01-31 2009-11-20 Актимис Фармасьютикалз, Инк. Производные имидазо[1,2-c]пиримидинилуксусной кислоты
AU2005260031B2 (en) * 2004-06-25 2008-10-09 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2007002177A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de pirrolo-naftilo como inhibidores de pai-1.
EP1794138A2 (en) 2004-08-23 2007-06-13 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
BRPI0514544A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
NZ561000A (en) 2005-02-28 2010-01-29 Japan Tobacco Inc Novel aminopyridine compound with Syk inhibitory activity
US7442700B2 (en) 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009511528A (ja) * 2005-10-13 2009-03-19 グラクソ グループ リミテッド Ｓｙｋ阻害物質としてのピロロピリミジン誘導体群
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
SI3034075T1 (sl) * 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
JPWO2008081928A1 (ja) 2006-12-28 2010-04-30 大正製薬株式会社 ピラゾロピリミジン化合物
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
NZ584351A (en) 2007-09-25 2012-03-30 Actimis Pharmaceuticals Inc 2-S-benzyl substituted pyrimidines as CRTH2 antagonists
EP2205569B1 (en) 2007-09-25 2012-02-29 Actimis Pharmaceuticals, Inc., Alkylthio pyrimidines as crth2 antagonists
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
SG171993A1 (en) 2008-12-08 2011-07-28 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
PT2716157T (pt) 2008-12-08 2016-08-23 Gilead Connecticut Inc Imidazopirazinas ¿ inibidores de syc
ES2632220T3 (es) * 2009-06-15 2017-09-11 Rigel Pharmaceuticals, Inc. Inhibidores de moléculas pequeñas de tirosina cinasa del bazo (SYK)
PH12012501311A1 (en) 2009-12-23 2016-07-22 Takeda Pharmaceuticals Co Fused heteroaromatic pyrrolidinones as syk inhibitors
MX350010B (es) 2010-03-11 2017-08-23 Gilead Connecticut Inc Inhibidores syk de imidazopiridinas.
CN102985424B (zh) * 2010-04-14 2015-03-11 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのピリジルアミノピリジン
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
JP2014513686A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのアミノピリミジン
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
SG11201401342VA (en) * 2011-10-12 2014-09-26 Array Biopharma Inc 5,7-substituted-imidazo[1,2-c]pyrimidines
EP2799431B1 (en) * 2011-12-28 2018-01-24 FUJIFILM Corporation Novel nicotinamide derivative or salt thereof
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
EP2863913B1 (en) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192098A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2884982B1 (en) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
WO2014100314A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9745295B2 (en) 2013-04-26 2017-08-29 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
SG11201600385TA (en) 2013-07-30 2016-02-26 Gilead Connecticut Inc Polymorph of syk inhibitors
PT3027171T (pt) 2013-07-30 2020-06-18 Gilead Connecticut Inc Formulação de inibidores da syk
DK3076976T3 (da) 2013-12-04 2020-12-07 Kronos Bio Inc Fremgangsmåder til behandling af cancer
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3082807B1 (en) 2013-12-20 2018-07-04 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
CN106255689B (zh) 2014-03-19 2019-09-17 勃林格殷格翰国际有限公司 杂芳基syk抑制剂
SG11201610551TA (en) 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
EP3347353B1 (en) 2015-09-11 2019-07-17 Boehringer Ingelheim International GmbH Pyrazolyl-substituted heteroaryls and their use as medicaments
JP6986624B2 (ja) 2017-08-25 2021-12-22 ギリアード サイエンシーズ， インコーポレイテッド Ｓｙｋ阻害剤の多形体
CA3079292A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
EP3710007A4 (en) * 2017-11-14 2021-12-15 Children's Medical Center Corporation USE OF IMIDAZOPYRIMIDINE TO MODULATE A HUMAN IMMUNE RESPONSE
JP7304855B2 (ja) 2017-11-14 2023-07-07 ザ チルドレンズ メディカル センター コーポレーション 新規イミダゾピリミジン化合物およびそれらの使用
JP7370079B2 (ja) * 2018-06-06 2023-10-27 国立大学法人北海道大学 グリオーマの処置剤および医薬組成物
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
AU2019373221B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
WO2020172431A1 (en) 2019-02-22 2020-08-27 Gilead Sciences, Inc. Solid forms of condensed pyrazines as syk inhibitors
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
EP1017682A4 (en) * 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
US6432963B1 (en) * 1997-12-15 2002-08-13 Yamanouchi Pharmaceutical Co., Ltd. Pyrimidine-5-carboxamide derivatives
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
CN1263756C (zh) 2006-07-12
MA25746A1 (fr) 2003-04-01
US6911443B2 (en) 2005-06-28
BR0110404A (pt) 2003-02-11
PL358106A1 (en) 2004-08-09
MXPA02010579A (es) 2003-05-14
AR033367A1 (es) 2003-12-17
UA72615C2 (en) 2005-03-15
EE200200606A (et) 2004-04-15
DE60104671T2 (de) 2005-12-29
AU6220401A (en) 2001-11-12
SK15332002A3 (sk) 2003-06-03
TWI222974B (en) 2004-11-01
ES2225546T3 (es) 2005-03-16
JP2003535067A (ja) 2003-11-25
AU783043B2 (en) 2005-09-22
SV2001000416A (es) 2001-07-03
RU2306313C2 (ru) 2007-09-20
HUP0300846A2 (hu) 2003-08-28
DE60104671D1 (de) 2004-09-09
JP2001302667A (ja) 2001-10-31
CN1439009A (zh) 2003-08-27
BG107166A (bg) 2003-06-30
US20040054179A1 (en) 2004-03-18
WO2001083485A1 (en) 2001-11-08
NZ522241A (en) 2004-04-30
HK1058362A1 (en) 2004-05-14
MY141578A (en) 2010-05-14
EP1278750A1 (en) 2003-01-29
HRP20020943A2 (en) 2005-02-28
PT1278750E (pt) 2004-11-30
PE20011287A1 (es) 2002-02-27
NO20025154L (no) 2002-10-25
SI1278750T1 (en) 2005-02-28
ZA200207676B (en) 2003-09-25
ATE272639T1 (de) 2004-08-15
IL151919A0 (en) 2003-04-10
DOP2001000151A (es) 2002-05-15
NO20025154D0 (no) 2002-10-25
EP1278750B1 (en) 2004-08-04
NZ526221A (en) 2005-01-28
KR20030009456A (ko) 2003-01-29
CZ20023551A3 (cs) 2003-01-15
CA2407531A1 (en) 2001-10-25
DK1278750T3 (da) 2004-11-22

Similar Documents

Publication Publication Date Title
TR200402300T4 (tr) İmidazopirimidin türevleri ve triazolopirimidin türevleri.
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
NL350077I2 (nl) Cyprosulfamide
TW200606137A (en) Urea derivatives
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
ECSP045294A (es) Derivados de 2,4-diaminopirimidina
PT1140916E (pt) Acetais heteroarilo ciclicos
DE69927039D1 (de) Synthetische analoge des ecteinascidin-743
AR026351A1 (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii
SE9702773D0 (sv) Novel compounds
ATE359073T1 (de) Benzylidenthiazolidindione und ihre verwendung als antimykotische mittel
EA200200558A1 (ru) 2-( 1h-индол-3-ил)-2-оксоацетамиды, обладающие противоопухолевой активностью
ATE170865T1 (de) Festfase bei oligonukleotidsynthese
DK1086096T3 (da) Benzamider med tetrahydrofuranyloxy-substituenter som inhibitorer af phosphodiesterase 4
PE20000734A1 (es) Compuestos heterociclicos derivados de furopiridina y su uso terapeutico
ATE286887T1 (de) Antibakterielle mittel
CO5180541A1 (es) Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
DK0601191T3 (da) Hidtil ukendt tetracyklisk forbindelse
DE60237652D1 (de) Variolinderivate und ihre Verwendung als Cytostatika
ATE123025T1 (de) 2-amino-n-(((4-(aminocarbonyl)pyrimidin-2- yl>amino>alkyl>-pyrimidin-4- carbonsäureamidderivate, ihre herstellung und ihre anwendung in der therapeutica.
TR200103215T2 (tr) 6-[[(Aril ve heteroaril)oksi]metil]naftalin-2-karboksimidamid türevleri, bunların hazırlanması ve terapötik uygulamaları
JPS57209231A (en) N-alkylation of nitrogen-containing organic compound
CA2053705A1 (en) Piperazine derivatives
FI811266L (fi) Antihypertensiva laktamer
TR199901474T2 (tr) Imisazol türevleri için proses.